Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

Projektinformationen

FGFSTAB

ID Finanzhilfevereinbarung: 756471

DOI 10.3030/756471

Projekt abgeschlossen

EK-Unterschriftsdatum 22 Februar 2017

Startdatum 1 März 2017

Enddatum 28 Februar 2019

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 1 030 000,00

EU-Beitrag € 1 030 000,00

Koordiniert durch

ENANTIS SRO
Czechia

Ziel

The FGFSTAB project closes the gap between Enantis knowledge and expertise on protein engineering and the commercial applications of stable fibroblast growth factors (FGFs). FGFs are essential to the embryonic development, maintain tissue homeostasis, may slow down ageing of the organisms, and primarily promote angiogenesis and wound healing. FGFs see the greatest application in the care and treatment of chronic skin ulcers, but find use also in surgical and trauma wound healing. The global wound care market is rapidly growing due to the rising aging population and growing incidences of obesity and diabetes. Advanced wound dressings, such as those involving growth factors, play an important role in current regenerative medicine and companies around the world have started investing heavily in research and development of growth factor-based products. However, despite clinical value, applications of FGFs are limited by the fact that natural proteins have poor thermal stability and a short half-life in the circulation; they are often cleared from the body within hours, if not minutes, thus necessitating frequent administrations during the course of treatment, which goes hand in hand with a higher risk of adverse effects and lower cost-effectiveness of the protein therapy. The key objective of the FGFSTAB project is to use an innovative technological platform, based on the application of Enantis proprietary protein optimization concept FireProt, to increase FGF stability under various stress conditions. Additional challenges including high cost of production, current Good Manufacturing Practise, development of delivery systems for safe and effective wound healing, and pre-clinical testing to support future clinical trials and marketing authorization, will be targeted as well. Financial support provided within SME Instrument phase 2 will help us to close the gap from demanding biotechnological development to the target industrial application in regenerative medicine.

Wissenschaftliches Gebiet

• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• natural sciences › biological sciences › developmental biology
• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › basic medicine › physiology › homeostasis
• medical and health sciences › health sciences › nutrition › obesity

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

ENANTIS SRO

• Netto-EU-Beitrag: € 1 030 000,00
• Adresse: KAMENICE 771/34 ; 625 00 Brno ; Tschechien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Česko › Jihovýchod › Jihomoravský kraj
• Region: Česko › Jihovýchod › Jihomoravský kraj
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 1 030 000,00